<DOC>
	<DOCNO>NCT01995006</DOCNO>
	<brief_summary>The plan study single-center , randomize , open-label parallel group study 16 healthy male subject . Study subject randomly allocate either metamizole group ( 1 ) naproxen group ( 2 ) . All participant start low sodium diet ( approximately 50 mmol Na+ per day ) 7 day first drug intake maintain diet end study ( 14 day total ) . Salt-depletion accept model enhance production vasodilatory prostaglandins increase renal sensitivity prostaglandin inhibition . On first day treatment ( Day 1 ) , single dose metamizole naproxen administer investigate effect single dose collect single dose pharmacokinetic profile . Starting Day 2 , participant receive therapeutic dos , i.e . 1000 mg metamizole 'ter die ' ( TID , three time day ) 500 mg naproxen 'bis die ' ( BID , twice day ) one week Day 7 pharmacokinetics pharmacodynamics effect assess near steady-state condition . The primary objective characterization renal effect metamizole determination glomerular filtration rate ( GFR ) use inulin clearance . Secondary objective characterization urinary excretion prostaglandin E2 ( PGE2 ) prostaglandin I2 ( PGI2 ) metabolite 6-keto-prostaglandin F1 ( PGF1 ) alpha well urinary excretion sodium potassium . Overall , clinical experience suggest well renal tolerability metamizole possibly due less potent COX-inhibition compare classical nonsteroidal antiinflammatory drug ( NSAIDs ) . If could confirm , metamizole would valuable alternative treatment painful condition patient impaired renal function . Therefore , aim study examine effect metamizole renal function comparison non-specific COX-inhibitor naproxen .</brief_summary>
	<brief_title>Effect Metamizole ( Dipyrone ) Renal Function Salt-depleted Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Dipyrone</mesh_term>
	<criteria>Healthy male subject age 18 45 year ( inclusive ) screen BMI 18 28 kg/m2 ( inclusive ) body weight least 50 kg screening . systolic blood pressure ( SBP ) : 100140 mmHg , diastolic blood pressure ( DBP ) : 6090 mmHg heart rate ( HR ) : 4590 bpm ( inclusive ) , measure leading arm* , supine position screen . No clinically significant finding physical examination screening . 12lead ECG without clinically relevant abnormality screen . Signed informed consent prior studymandated procedure . Hematology clinical chemistry result deviate normal range clinically relevant extent screening . Ability communicate well investigator understand comply requirement study . lead arm right = write right hand Smoking &gt; 5 cigarette per day . History clinical evidence alcoholism drug abuse within 3year period prior screen . Loss â‰¥ 250 ml blood within 3 month prior screen . Treatment investigational drug within 30 day prior screen . Previous treatment prescribe overthecounter ( OTC ) medication ( include herbal medicine St John 's Wort ) within 2 week prior intend start study . Legal incapacity limit legal capacity screening . Positive result urine drug screen screen . History clinical evidence disease ( e.g . GITdisease : Morbus Crohn , Colitis Ulcerosa , anamnestic gastrointestinal bleeding ) and/or existence surgical medical condition , might interfere absorption , distribution , metabolism excretion study drug , might increase risk toxicity . Known hypersensitivity Aspirin NSAIDs excipients drug formulation . Known food allergy , make adherence diet impossible Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Effect</keyword>
	<keyword>metamizole</keyword>
	<keyword>salt-depleted</keyword>
	<keyword>subject</keyword>
</DOC>